156 related articles for article (PubMed ID: 24167685)
1. Plasma quetiapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2000-2011.
Handley SA; Bowskill SV; Patel MX; Flanagan RJ
Ther Adv Psychopharmacol; 2013 Jun; 3(3):129-37. PubMed ID: 24167685
[TBL] [Abstract][Full Text] [Related]
2. Plasma concentrations of quetiapine, N-desalkylquetiapine, o-desalkylquetiapine, 7-hydroxyquetiapine, and quetiapine sulfoxide in relation to quetiapine dose, formulation, and other factors.
Fisher DS; Handley SA; Flanagan RJ; Taylor DM
Ther Drug Monit; 2012 Aug; 34(4):415-21. PubMed ID: 22777152
[TBL] [Abstract][Full Text] [Related]
3. Measurement of quetiapine and four quetiapine metabolites in human plasma by LC-MS/MS.
Fisher DS; Handley SA; Taylor D; Flanagan RJ
Biomed Chromatogr; 2012 Sep; 26(9):1125-32. PubMed ID: 22241669
[TBL] [Abstract][Full Text] [Related]
4. Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994-2010.
Couchman L; Bowskill SV; Handley S; Patel MX; Flanagan RJ
Early Interv Psychiatry; 2013 May; 7(2):122-30. PubMed ID: 22747759
[TBL] [Abstract][Full Text] [Related]
5. Quetiapine : A Review of its Use in Schizophrenia.
Gunasekara NS; Spencer CM
CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients.
Bakken GV; Rudberg I; Molden E; Refsum H; Hermann M
Ther Drug Monit; 2011 Apr; 33(2):222-6. PubMed ID: 21383647
[TBL] [Abstract][Full Text] [Related]
7. Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review.
Sparshatt A; Taylor D; Patel MX; Kapur S
J Clin Psychiatry; 2011 Aug; 72(8):1108-23. PubMed ID: 21294996
[TBL] [Abstract][Full Text] [Related]
8. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.
Couchman L; Morgan PE; Spencer EP; Flanagan RJ
Ther Drug Monit; 2010 Aug; 32(4):438-47. PubMed ID: 20463634
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders.
Gerlach M; Hünnerkopf R; Rothenhöfer S; Libal G; Burger R; Clement HW; Fegert JM; Wewetzer Ch; Mehler-Wex C
Pharmacopsychiatry; 2007 Mar; 40(2):72-6. PubMed ID: 17447177
[TBL] [Abstract][Full Text] [Related]
10. Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002-2010.
Bowskill SV; Patel MX; Handley SA; Flanagan RJ
Hum Psychopharmacol; 2012 Sep; 27(5):507-13. PubMed ID: 22996618
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.
Mauri MC; Volonteri LS; Colasanti A; Fiorentini A; De Gaspari IF; Bareggi SR
Clin Pharmacokinet; 2007; 46(5):359-88. PubMed ID: 17465637
[TBL] [Abstract][Full Text] [Related]
12. Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients.
Bakken GV; Molden E; Hermann M
Ther Drug Monit; 2015 Apr; 37(2):256-61. PubMed ID: 25254417
[TBL] [Abstract][Full Text] [Related]
13. Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2009.
Patel MX; Bowskill S; Couchman L; Lay V; Taylor D; Spencer EP; Flanagan RJ
J Clin Psychopharmacol; 2011 Aug; 31(4):411-7. PubMed ID: 21694620
[TBL] [Abstract][Full Text] [Related]
14. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders.
Winter HR; Earley WR; Hamer-Maansson JE; Davis PC; Smith MA
J Child Adolesc Psychopharmacol; 2008 Feb; 18(1):81-98. PubMed ID: 18294091
[TBL] [Abstract][Full Text] [Related]
15. Effect of N-Desalkylquetiapine/Quetiapine Plasma Level Ratio on Anxiety and Depression in Bipolar Disorder: A Prospective Observational Study.
Rovera C; Mauri MC; Di Pace C; Paletta S; Reggiori A; Ciappolino V; Cattaneo D; Baldelli S; Clementi E; Altamura AC
Ther Drug Monit; 2017 Aug; 39(4):441-445. PubMed ID: 28486308
[TBL] [Abstract][Full Text] [Related]
16. Relationship Between Daily Dose, Serum Concentration, and Clinical Response to Quetiapine in Children and Adolescents with Psychotic and Mood Disorders.
Albantakis L; Egberts K; Burger R; Kulpok C; Mehler-Wex C; Taurines R; Unterecker S; Wewetzer C; Romanos M; Gerlach M
Pharmacopsychiatry; 2017 Nov; 50(6):248-255. PubMed ID: 28561203
[No Abstract] [Full Text] [Related]
17. Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002-2010.
Bowskill SV; Handley SA; Fisher DS; Flanagan RJ; Patel MX
Ther Drug Monit; 2012 Jun; 34(3):349-55. PubMed ID: 22569353
[TBL] [Abstract][Full Text] [Related]
18. Quetiapine for schizophrenia.
Srisurapanont M; Maneeton B; Maneeton N
Cochrane Database Syst Rev; 2004; 2004(2):CD000967. PubMed ID: 15106155
[TBL] [Abstract][Full Text] [Related]
19. Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies.
Citrome L; Jaffe A; Levine J; Lindenmayer JP
J Clin Psychiatry; 2005 Dec; 66(12):1512-6. PubMed ID: 16401150
[TBL] [Abstract][Full Text] [Related]
20. Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers.
Estevez-Carrizo FE; Parrillo S; Ercoli MC; Estevez-Parrillo FT
Clin Ther; 2011 Jun; 33(6):738-45. PubMed ID: 21704238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
